SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the Trump administration is reportedly in talks to take equity stakes in quantum computing firms, potentially providing a boost to the sector. The community is actively discussing the implications of this government involvement and whether it will trigger a short squeeze. Amidst this news, there are debates regarding the company's valuation and future prospects within the quantum computing landscape.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending amid discussions of potential government investment in quantum computing firms, sparking debates about the sector's speculative nature and long-term potential.  Community members are weighing the significance of this backing, while some express skepticism about the technology's current valuation and practical applications. The news is driving volatility, with both bulls and bears actively strategizing around potential price movements.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid discussions about a potential equity stake from the Trump administration in exchange for federal funding, as reported by the WSJ. Community chatter revolves around the potential impact of this news, with some anticipating a short squeeze while others express skepticism about the amount of funding. There is debate about how this government involvement will impact the quantum computing sector, which also includes names such as IONQ and RGTI.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending as discussion centers around the potential impact of government investment in quantum computing firms and the company's positioning with its 'Made in USA' post-quantum chips. Community members are actively debating the possibility of a short squeeze, comparing it to past events with other quantum stocks, while also pointing to potential government contracts on the horizon. Talk also focuses on the impact of the latest stock offering on price action.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending as investors digest its latest earnings report, with key talking points revolving around AI advancements and the future of robotaxis. The community is actively debating the company's profitability, growth prospects, and Elon Musk's vision amid discussions of potential market overvaluation. Sentiment appears mixed, with some expressing concerns about margins and future performance, while others remain optimistic about Tesla's long-term potential in AI and robotics.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as the community discusses its potential in the quantum computing space, particularly its ties to Infleqtion and government backing. Recent news about Infleqtion's involvement in upcoming AI and quantum conferences, as well as potential partnerships, are fueling interest. Some investors believe $CCCX is undervalued compared to its peers in the sector, while others are wary of market volatility and potential risks associated with SPAC mergers.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is trending amid community discussion around large, out-of-the-money call option buying, specifically the Nov 21 $385 strike, which some speculate could be tied to potential acquisition news or regulatory changes. Some traders are pointing to the upcoming lockup period expiration and earnings as potential catalysts, while others highlight Wells Fargo's updated overweight rating with a $160 price target as a positive signal.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to positive reactions to the company's quantum computing advancements, specifically its partnership with HSBC to improve bond-trading predictions, causing a significant market cap increase. Community discussions highlight IBM's potential in AI and quantum computing, with some seeing it as undervalued compared to other quantum stocks. However, the stock experienced after-hours volatility despite a Q3 revenue beat and raised guidance, leading to mixed sentiments about short-term performance.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals ($ARMP) is trending after promising Phase 2a trial results for its phage therapy targeting Staph aureus bacteremia, with community members highlighting the potential for a new standard of care and the stock's volatile price action. Bullish sentiment focuses on the news catalyst, small float, and backing from Innoviva and the U.S. government, while bears cite potential dilution and historical volatility.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending, with community members actively promoting its Telegram and X communities. The coin is being touted as an alternative to Bitcoin, but "way higher", with focus on community, culture, and steady growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?

The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Tesla, AeroVironment and Progress Software fall premarket; MSC Industrial rises

Investing.com -- U.S. stock futures slipped lower Tuesday, dropping back from record levels as investors digested the latest news on trade deals, the Trump administration’s tax bill as well as upcoming key economic data.

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy type 1 (DM1).Dyne said it will now use video hand opening time (vHOT) as the primary endpoint, which measures the change from baseline in middle finger myotonia at six months compared to placebo.&nbsp;The update follows a Type C meeting with the U.S. Food and Drug Administration, which agreed vHOT could serve as an intermediate clinical endpoint to support a future submission for accelerated approval.The revised protocol was submitted to the FDA earlier this month.&nbsp;Dyne plans to complete enrollment in the expansion cohort during the fourth quarter, with 60 participants randomized 3:1 to receive either DYNE-101 or placebo.The revised expansion cohort will consist of 60 participants, randomized 3:1 to receive DYNE-101 at 6.8 mg/kg every eight weeks or placebo.&nbsp;Secondary endpoints include measures of muscle strength, walking performance, splicing biomarkers, and patient-reported outcomes.&nbsp;Enrollment is expected to be completed in Q4 2025, with pivotal data expected in mid-2026.Data from the 12-month cohort of the MAD study showed sustained effects on all measures, including vHOT and strength testing, where patients improved by 20% from baseline.&nbsp;The company also reported a favorable safety profile, with no treatment-related serious adverse events in the 56 participants dosed to date.Dyne plans to initiate a confirmatory Phase 3 trial in early 2026.&nbsp;It also reiterated that its cash balance of $677.5 million as of March 31 will fund operations into Q4 2026.Stifel analyst Paul Matteis said the change “comes as a surprise” and “will raise questions,” though he maintained a ‘Buy’ rating on the stock, suggesting the move could offer a clearer approval route.&nbsp;Meanwhile, H.C. Wainwright called the change “encouraging,” noting that powering the trial to 60 participants could improve confidence in vHOT and help detect trends across secondary endpoints.Chardan Capital also reiterated a ‘Buy’ rating and said the FDA’s confirmation of an accelerated pathway “more than offsets” a potential six-month delay to a Biologics License Application (BLA).&nbsp;The firm described the pullback as an “attractive entry point,” with the stock down 41% year-to-date.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial

The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes. 

Equity

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

DYN
Dyne Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DYN News

DYNDyne Therapeutics Inc